These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28785316)

  • 21. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study.
    Nishimura R; Osonoi T; Kanada S; Jinnouchi H; Sugio K; Omiya H; Ubukata M; Sakai S; Samukawa Y
    Diabetes Obes Metab; 2015 Aug; 17(8):800-4. PubMed ID: 25930989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of daily glycemic profiles in well controlled children with type 1 diabetes mellitus using a continuous glucose monitoring system.
    Tucholski K; Deja G; Skała-Zamorowska E; Jarosz-Chobot P
    Pediatr Endocrinol Diabetes Metab; 2009; 15(1):29-33. PubMed ID: 19454186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial.
    Garg S; Zisser H; Schwartz S; Bailey T; Kaplan R; Ellis S; Jovanovic L
    Diabetes Care; 2006 Jan; 29(1):44-50. PubMed ID: 16373894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.
    List JF; Whaley JM
    Kidney Int Suppl; 2011 Mar; (120):S20-7. PubMed ID: 21358698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SGLT2 Inhibitors May Predispose to Ketoacidosis.
    Taylor SI; Blau JE; Rother KI
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2849-52. PubMed ID: 26086329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
    Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
    Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring.
    Yamada K; Nakayama H; Yoshinobu S; Kawano S; Tsuruta M; Nohara M; Hasuo R; Akasu S; Tokubuchi I; Wada N; Hirao S; Iwata S; Kaku H; Tajiri Y
    J Diabetes Investig; 2015 Nov; 6(6):699-707. PubMed ID: 26543545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
    Danne T; Biester T; Kordonouri O
    Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
    Gallo LA; Wright EM; Vallon V
    Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
    Fattah H; Vallon V
    Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
    Pfeifer M; Townsend RR; Davies MJ; Vijapurkar U; Ren J
    Cardiovasc Diabetol; 2017 Feb; 16(1):29. PubMed ID: 28241822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.
    Yoshimoto T; Furuki T; Kobori H; Miyakawa M; Imachi H; Murao K; Nishiyama A
    J Investig Med; 2017 Oct; 65(7):1057-1061. PubMed ID: 28596160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing Patient Satisfaction Following Sodium Glucose Co-Transporter 2 Inhibitor Treatment for Type 1 Diabetes Mellitus: A Prospective Study in Japan.
    Ishibashi R; Baba Y; Kakinuma K; Takasaki A; Hiraga C; Harama T; Yamamoto T; Nakamura S; Koshizaka M; Maezawa Y; Uchida D; Okajima F
    Diabetes Ther; 2021 Jan; 12(1):453-460. PubMed ID: 33237553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study.
    Kinoshita T; Shimoda M; Sanada J; Fushimi Y; Hirata Y; Irie S; Obata A; Kimura T; Hirukawa H; Kohara K; Tatsumi F; Kamei S; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Ther; 2018 Aug; 9(4):1569-1580. PubMed ID: 29931506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erratum to: Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.
    Kalra S
    Diabetes Ther; 2015 Mar; 6(1):95. PubMed ID: 25588327
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.